natgillin/translations-raw huggingface dataset:
Method according to any one of the preceding claims, characterized in that the filter in the first and second filter unit have about the same filter area. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da filter u prvoj filterskoj jedinici ima istu filtersku površinu kao i filter u drugoj filterskoj jedinici.
Method according to any one of claims 2 to 6, characterized in that the purifying is with a protein A affinity chromatography step and at least one step selected from cation exchange chromatography, anion exchange chromatography, and hydrophobic interaction chromatography. 
Postupak prema bilo kojem od zahtjeva 2 do 6, naznačen time, da se pročišćivanje vrši kroz fazu kromatografije afiniteta na protein-A i kroz najmanje jednu fazu odabranu od kromatografije kationske izmjene, kromatografije anionske izmjene i kromatografije hidrofobne interakcije.
Method according to any one of the preceding claims, characterized in that the immunoglobulin solution has a concentration of 160 g/l or more and the applying to the combination of filters is by applying a pressure of 1.45 bar or more. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da otopina imunoglobulina ima koncentraciju od 160 g/l ili više, te se nanošenje na kombinaciju filtera vrši primjenom tlaka od 1,45 bara ili više.
Method according to any one of claims 1 to 7, characterized in that the immunoglobulin solution comprises a sugar and a surfactant and has a concentration of 125 mg/ml or more and the applying to the combination of the filter is by applying a pressure of 0.75 bar or less. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da otopina imunoglobulina sadrži šećer i tenzid i ima koncentraciju od 125 mg/ml ili više, te se nanošenje na kombinaciju filtera vrši primjenom tlaka od 0,75 bara ili manje.
The pharmaceutical composition according to claim 1, wherein the therapeutically effective amount of desmopressin is administered in the form of desmopressin acetate. 
Farmaceutski pripravak prema zahtjevu 1, gdje se terapijski učinkovita količina dezmopresina primjenjuje u obliku dezmopresin acetata.
Subjecting said preparation to filtration for at least about 24 hours through a virus filter having an effective pore size of maximum 75 nm. 
podvrgavanje tog pripravka filtraciji kroz najmanje 24 sata kroz virusni filter s učinkovitom veličinom pora od najviše 75 nm i volumetrijskim kapacitetom od najmanje oko 2000 L/m2.
Use of a virus filter having an effective pore size of maximum 75 nm in a filtration for at least 24 hours for the removal of viral contaminant from a preparation, being a cell culture medium or at least a component of a cell culture medium. 
Uporaba virusnog filtra s učinkovitom veličinom pora od najviše 75 nm i volumetrijskim kapacitetom od najmanje oko 2000 L/m2 u filtraciji kroz najmanje 24 sata radi uklanjanja virusnog onečišćenja iz pripravka koji je medij stanične kulture ili barem komponenta medija stanične kulture.
The method or use of claim 1 or 2, wherein the filtration operates at a volumetric capacity of at least about 2000 L/m2, preferably at least about 3000 L/m2, most preferably at least about 5000 L/m2. 
Postupak ili uporaba prema zahtjevu 1 ili 2, gdje se filtracija provodi uz volumetrijski kapacitet od najmanje oko 3000 L/m2, poželjno od najmanje oko 5000 L/m2.
The method or use of any of claims 1 to 7, wherein said virus filter achieves at least a 1 Log10 reduction value (LRV) for a viral contaminant, preferably at least a 4 Log10 reduction value (LRV) for a viral contaminant and most preferably at least 6Log10 reduction value (LRV) for a viral contaminant. 
Postupak ili uporaba prema bilo kojem od zahtjeva 1 do 7, gdje taj virusni filter daje vrijednost smanjenja od najmanje 1 Log10 (engl. Log10 reduction value, LRV) za virusno onečišćenje, poželjno vrijednost smanjenja od najmanje 4 Log10 (LRV) za virusno onečišćenje i najpoželjnije vrijednost smanjenja od najmanje 6 Log10 (LRV) za virusno onečišćenje.
The method or use of claim 9, wherein filtration is performed using two filters arranged in parallel in a system of tubes comprising a Y-shaped junction and wherein each filter is in fluid communication with a branch of the Y-shaped junction and a preparation supply source. 
Postupak ili uporaba prema zahtjevu 9, gdje se filtracija provodi uz uporabu dva filtra raspoređena u paralelu u sustavu cijevi koji ima spoj Y-oblika i gdje je svaki filter u protočnoj vezi s granom spoja Y-oblika i izvorom dopreme pripravka.
A compound comprising a peptide wherein the peptide comprises the amino acid sequence: 
Spoj, koji obuhvaća peptid i konjugirajuću skupinu, gdje peptid sadrži aminokiselinsku sekvencu formule:
The compound of claim 1 or claim 2, wherein at least two of X2, X3 and X4 are independently a cationic amino acid. 
gdje su barem dva od X2, X3 i X4 nezavisno kationska podjedinica; i gdje je peptid vezan na svom N-kraju disulfidnom vezom za konjugirajuću skupinu.
A solid non-edible composition according to claim 1, wherein the vegetable butter is a mixture of two or more vegetable butters. 
Kruti nejestivi pripravak prema zahtjevu 1, naznačen time da biljni maslac je smjesa dva ili više biljnih maslaca.
A solid non-edible composition according to claim 3, wherein the vegetable butter is a mixture of cocoa butter and shea butter. 
Kruti nejestivi pripravak prema zahtjevu 3, naznačen time da biljni maslac je smjesa kakao maslaca i shea maslaca.
cocoa butter in an amount of from 70% to 85% by weight of the total composition 
kakao maslac u količini od 70% do 85% težinski cjelokupnog pripravka
shea butter in an amount of from 10% to 25% by weight of the total composition 
shea maslac u količini od 10% do 25% težinski cjelokupnog pripravka
A solid non-edible composition according to any one of claims 1 to 9 wherein the composition comprises a shell coating, wherein the shell coating is a material which is not aerated, and wherein the shell coating is formed from the same material as the solid composition having dispersed therein gas bubbles. 
Kruti nejestivi pripravak prema bilo kojem od zahtjeva 1 do 9 naznačen time da pripravak sadrži premaz ljuske, pri čemu premaz ljuske je materijal koji nije aeriran, te pri čemu je premaz ljuske dobiven od istog materijala kao kruti pripravak koji ima u sebi dispergirane mjehuriće plina.
ii) applying a pressure reduction to the melted butter such that gas bubbles are formed within the melted one or more vegetable butters; and iii) allowing the mixture of step ii) to solidify. 
ii) primjenu smanjenja tlaka na rastaljeni maslac tako da mjehurići plina su formirani unutar rastaljenog jednog ili više biljnih maslaca; i iii) ostavljanje da se smjesa iz koraka ii) skrutne.
A compound selected from: 
Spoj je odabran od:
A composition comprising a compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Kompozicija koja sadrži spoj iz bilo kojeg od patentnih zahtjeva 1 do 6, ili farmaceutski prihvatljivu sol tog spoja, i farmaceutski prihvatljiv nosač tog spoja.
The composition of claims 8, wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection. 
Kompozicija iz patentnog zahtjeva 8, gdje je najmanje jedan od dodatnih spojeva efikasan da inhibira funkciju targeta koji je odabran od HCV metaloproteinaze, HCV serin proteaze, HCV polimeraze, HCV helikaze, HCV NS4B proteina, HCV ulaska, HCV sklapanja, HCV izlaska, HCV NS5A proteina, i IMPDH za lečenje HCV infekcije.
A compound, or a pharmaceutically acceptable salt thereof, for use according to claim 13, wherein the interferon is selected from interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastiod interferon tau. 
Spoj, ili njegova farmaceutski prihvatljiva sol, za primjenu prema patentnom zahtjevu 13, gdje je interferon odabran od interferona alfa 2B, pegiliranog interferona alfa, konsenzus interferona, i limfoblastoidnog interferona tau.
A compound, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 12 to 14, wherein at least one of the additional compounds is effective to inhibit the function of a target selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, and IMPDH for the treatment of an HCV infection. 
Spoj, ili njegova farmaceutski prihvatljiva sol, za primjenu prema bilo kojem od patentnih zahtjeva 12 do 14, gdje je najmanje jedan od dodatnih spojeva efikasan da inhibira funkciju targeta koji je odabran od HCV metaloproteinaze, HCV serin proteaze, HCV polimeraze, HCV helikaze, HCV NS4B proteina, HCV ulaska, HCV sklapanja, HCV izlaska, HCV NS5A proteina, i IMPDH za liječenje HCV infekcije.
Method according to claim 1, wherein the second carrier frequency (120) is a frequency in a frequency range out of the following: 
Postupak prema zahtjevu 1, pri čemu je druga noseća frekvencija (120) nelicencirana frekvencija, a osobito frekvencija u ISM-radio frekventnom opsegu.
Computer program product for enhancing the usable bandwidth between on the one hand an access point (15) of a radio access network (16) of a telecommunications network (10) and on the other hand a User Equipment (20), the computer program product comprising a computer program stored on a storage medium, the computer program comprising program code which, when executed on a antenna device means of the system according to claim 10, causes the system to perform a method according one of claims 1 to 9. 
od 244 GHz do 246 GHz. Računalni programski proizvod za povećanje raspoloživog frekventnog opsega između, sjedne strane, pristupne točke (15) pristupne radio mreže (16) telekomunikacijske mreže (10) i, s druge strane, korisničke opreme (20), pri čemu računalni programski proizvod sadrži računalni program koji je smješten na mediju za čuvanje podataka, a računalni program sadrži programski kod koji, kada se izvršava na računalu, prouzrokuje da računalo izvršava postupak prema jednom od zahtjeva od 1 do 6.
contacting a sample obtained from a wound with at least three substrates for at least three enzymes selected from one of the following combinations: 
stavljanje u doticaj uzorka koji je dobiven iz rane s najmanje tri supstrata za najmanje tri enzima odabrana od jedne od sljedećih kombinacija:
detecting a wound infection when a conversion of the at least three substrates with said at least three enzymes is determined. 
otkrivanje infekcije u rani kada je utvrđena konverzija od najmanje tri supstrata s najmanje tri enzima.
Method according to claim 1, characterised in that the sample is contacted with at least four of said substrates. 
Postupak prema zahtjevu 1, naznačen time, da se uzorak stavlja u doticaj s najmanje četiri od navedenih supstrata.
Method according to claim 1 or 2, characterised in that the sample is wound fluid, a wound dressing comprising wound fluid, a swab comprising wound fluid. 
Postupak prema zahtjevu 1 ili 2, naznačen time, da uzorak je fluid iz rane, zavoj za previjanje rane koji sadrži fluid iz rane, tupfer s brisom koji sadrži fluid iz rane.
Wound dressing or swab according to claim 10 or 11, characterised in that said substrates are dispersed or covalently bound in a matrix of a medically acceptable polymer or bound on a fiber. 
Zavoj za previjanje rane ili tupfer prema zahtjevu 10 ili 11, naznačen time, da su navedeni supstrati raspršeni ili kovalentno vezani u matrici od medicinski prihvatljivog polimera ili su vezani na vlakno.
Wound dressing according to claim 10 or 11, characterised in that said substrates are selected from the group consisting of a peptidoglycan, preferably a peptidoglycan of Micrococcus lysodeictikus dyed with a vinyl sulfone dye, N-methoxysuccinyl-ala-ala-pro-val-p-nitroanilide, N-methoxysuccinyl-ala-ala-pro-phe p-nitroanilide, 3,3',5,5'-tetramethylbenzidin, 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid), crystal violet, leuko crystal violet, sinaptic acid and Fast Blue RR modified with Isocynat. 
Zavoj za previjanje rane prema zahtjevu 10 ili 11, naznačen time, da su navedeni supstrati odabrani iz skupine koju čine peptidoglikan, poželjno peptidoglikan od Micrococcus lysodeictikus obojan s vinilsulfonskom bojom, N-metoksisukcinil-ala-ala-pro-val-p-nitroanilid, N-metoksisukcinil-ala-ala-pro-phe-p-nitroanilid, 3,3',5,5'-tetrametilbenzidin, 2,2'-azino-bis-(3-etilbenztiazolin-6-sulfonska kiselina), kristalviolet, leukokristalviolet, sinaptička kiselina i Fast Blue RR modificiran s izocijanatom.
The use of claim 5, wherein the medicament improves H2O2-induced injury of PC12 cells, improves glutamic acid-induced injury of PC12 cells, inhibits expression or excretion of ICAM-1 by endothelial cells in cerebral vessels and/or inhibits the transformation of T- and B-lymphocytes. The use of any one of claims 1-6, wherein said mammal is human. 
Analgecine za uporabu kao lijek prema zahtjevu 1, gdje analgecine poboljšava H2O2-induciranu ozljedu PC12 stanica ili analgecine poboljšava ozljedu PC12 stanice induciranu glutaminskom kiselinom ili analgecine inhibira ekspresiju ili izlučivanje ICAM-1 iz endotelnih stanica u žilama mozga ili analgecine inhibira transformaciju T- i B-limfocita.
The compound or a pharmacologically acceptable salt thereof according to claim 1 or 2, wherein the heteroaryl group is a 5- or 6-membered nitrogen-containing aromatic heterocyclic group. 
Spoj ili njegova farmaceutski prihvatljiva sol prema patentnom zahtjevu 1 ili 2, pri čemu je heteroaril grupa 5- ili 6-člana aromatična heterociklična grupa koja sadrži azot.
The compound or a pharmacologically acceptable salt thereof according to any one of claims 1 to 4, wherein Ar1 is a pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazolyl group or imidazolyl group, optionally having as substituents one or two groups selected from the group consisting of a chlorine atom, a fluorine atom, a methyl group, an ethyl group, a trifluoromethyl group, an amino group, a methylamino group and a dimethylamino group. 
Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem patentnom zahtjevu od 1 do 4, pri čemu je Ar1 piridilil grupa, piridazinil grupa, pirimidinil grupa, pirazolil grupa ili imidazolil grupa, koja po izboru kao supstituente ima jednu ili dvije grupe odabrane iz grupe koja se sastoji od atoma klora, atoma fluora, metil grupe, etil grupe, trifluorometil grupe, amino grupe, metilamino grupe i dimetilamino grupe.
PTA-9017, or an antigen binding fragment thereof. 
PTA-9017, ili njegov antigenski vežući fragment.
A recombinant cell that expresses an antibody that specifically binds endosialin, said antibody produced by cells having ATCC Access. No. 
Rekombinantna stanica koja eksprimira protutijelo koje se specifično veže na endosijalin, naznačena time što navedeno protutijelo proizvode stanice s ATCC pristupnim br.
An antibody or antigen binding fragment for use according to claim 10, wherein said antibody or antigen-binding fragment inhibits the interaction of endosialin expressed on the surface of a cell with collagen or fibronectin. 
Protutijelo ili antigenski vežući fragment namijenjeni upotrebi u skladu s patentnim zahtjevom 10, naznačeni time što navedeno protutijelo ili antigenski vežući fragment inhibiraju međudjelovanje endosijalina eksprimiranog na površini stanice s kolagenom ili fibronektinom.
as a hollow sleeve; or as a hollow beaker open in proximity of the cutter edge (51) and cladding an internal bottom and an internal wall of the hollow body (50). 
kao šuplja cijev; ili kao otvor šuplje čaše u blizini oštrice sječiva (51) i koji oblaže unutarnje dno i unutarnji zid šupljeg tijela (50).
The closure according to any one of the preceding claims, characterised in that in the first configuration, in proximity of said cutter edge (51), the internal cavity (8) is in fluid communication with a portion of the first chamber (2) external of the hollow body (50). 
Zatvarač prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je u prvoj konfiguraciji, u blizini navedene oštrice sječiva (51), unutarnja šupljina (8) u fluidnoj komunikaciji sa dijelom prve komore (2) izvan šupljeg tijela (50). Pakiranje koje sadrži:
A monoclonal antibody or a fragment thereof, which recognizes full length human LIF, but does not recognize a LIF fragment corresponding to amino acids 1 to 160, wherein the antibody is produced by the hybridoma cell line DSM ACC3054, deposited on April 1st 2010 by Vall d'Hebron Institute of Oncology at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. 
Monoklonsko protutijelo ili njegov fragment, koji prepoznaju ljudski LIF pune duljine, no ne prepoznaju LIF fragment koji odgovara aminokiselinama od 1 do 160, naznačeni time što protutijelo proizvodi hibridomna stanična linija DSM ACC3054, deponirana 1. travnja 2010., od strane Onkološkog instituta Vall d’Hebron kod Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.
The hybridoma cell line DSM ACC3054, deposited on April 1st 2010 by Vall d'Hebron Institute of Oncology at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH. 
Hibridomna stanična linija DSM ACC3054, naznačena time što je deponirana 1. travnja 2010., od strane Onkološkog instituta Vall d’Hebron kod Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH.
The monoclonal antibody or fragment thereof for use according to claim 3, wherein said antibody or fragment thereof acts through the inhibition of the self-regeneration of tumor stem cells. 
Monoklonsko protutijelo, ili njegov fragment, namijenjeni upotrebi u skladu s patentnim zahtjevom 3, naznačeni time što navedeno protutijelo, ili njegov fragment, djeluje inhibiranjem samoregeneracije tumorskih matičnih stanica.
A pharmaceutical composition comprising a therapeutically effective amount of an antibody or fragment thereof according to claim 1 together with a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time što sadrži terapijski djelotvornu količinu protutijela, ili njegovog fragmenta, u skladu s patentnim zahtjevom 1, uz farmaceutski prihvatljiv nosač.
An immunoanalytical reagent used in the measurement of human LIF, which comprises the monoclonal antibody or fragment thereof according to claim 1. 
Imunoanalitički reagens koji se upotrebljava u mjerenju ljudskog LIF, naznačen time što sadrži monoklonsko protutijelo, ili njegov fragment, u skladu s patentnim zahtjevom 1.
Analgecine for use as a medicament according to claim 1, wherein analgecine improves H2O2-induced injury of PC12 cells or analgecine improves glutamic acid-induced injury of a PC12 cell or analgecine inhibits expression or excretion of ICAM-1 by an endothelial cell in a cerebral vessel or analgecine inhibits the transformation of T-and B-lymphocytes. 
Analgecine za uporabu kao lijek prema zahtjevu 1, gdje analgecine poboljšava H2O2-induciranu ozljedu PC12 stanica ili analgecine poboljšava ozljedu PC12 stanice induciranu glutaminskom kiselinom ili analgecine inhibira ekspresiju ili izlučivanje ICAM-1 iz endotelnih stanica u žilama mozga ili analgecine inhibira transformaciju T- i B-limfocita.
A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein; 
Spoj formule (I) ili odgovarajuća farmaceutski prihvatljiva sol: [image]
and R9 are each independently hydrogen or C1-C6 alkyl, or R8 and R9 may form together with the nitrogen atom to which they are attached a 5-11- membered saturated monocyclic or a fused or spiro bicyclic ring system optionally containing a further heteroatom which is oxygen or nitrogen, said nitrogen atom being optionally substituted by C1-C6 alkyl; wherein such C1-C6 alkyl groups may be optionally substituted by a group C1-C6 alkyl, C3-C6 cycloalkyl, hydroxyl or halo; 
[image] i R9 svaki neovisno jesu vodik ili C1–C6alkil, ili R8 i R9 mogu zajedno s dušikovim atomom za koji su vezani tvoriti 5-11-člani zasićeni monociklički ili fuzinirani ili spiro-biciklički sustav prstenova koji mogu dalje sadržavati heteroatom koji je kisik ili dušik, a rečeni dušikov atom može biti supstituiran s C1–C6alkilom, pri čemu takve C1–C6alkilne skupine mogu biti supstituirane skupinama C1–C6alkil, C3–C6cikloalkil, hidroksil ili halogen;
X1, X2, X3, X4 and X5 are each independently a carbon atom, a nitrogen atom, a group -(CH)- or a group -NH-; such that each combination thereof forms an aromatic ring system; 
, X2, X3, X4 i X5 svaki neovisno jest ugljikov atom, dušikov atom, skupina –(CH)– ili skupina –NH–, a takva da svaka njihova kombinacija tvori aromatski sustav prstena,
is linked to X4 and is selected from a group consisting of: 
je vezan za X4 i odabran je iz sljedeće skupine:
is a group of general formula (IV) wherein 
jest skupina opće formule (IV) [image]
or and R21 as defined above may form together with the carbon atom to which they are attached a saturated 3-7- membered monocyclic ring; 
ili i R21 kao što je gore definirano mogu zajedno s ugljikovim atomom za koji su vezani tvoriti zasićeni 3-7 člani monociklički prsten;
z1, z2, z3, and z4 are independently selected in the group consisting of: C, N, S, O, a group -CH-, and a group -NH-, in such a combination that the resulting ring formed is an aromatic system; 
, z2, z3 i z4 su neovisno odabrani iz sljedeće skupine: C, N, S, O, skupina –CH– te skupina –NH–, u takvoj kombinaciji da nastali tvoreni prsten jest aromatski sustav;
A compound of formula (I) according to claim 1 which is a compound of formula (Ia) wherein carbon stereogenic center on the cycloalkylene portion of ring A which is linked to group W and identified with number (1) herebelow, possess the absolute configuration herebelow represented: Or a pharmaceutically acceptable salt thereof. 
Spoj formule (I) prema patentnom zahtjevu 1 koji jest spoj formule (Ia), naznačen time da je stereogeni ugljikov centar cikloalkilenskog dijela prstena A koji je vezan za skupinu W i naznačen niže brojem (1) ima sljedeću apsolutnu konfiguraciju niže predstavljenu kao: [image] ili odgovarajuća farmaceutski prihvatljiva sol.
Wherein R11 is a group: Wherein R25 is optionally present and represents one, two or three substituents independently selected in the list consisting of: C1-C6 alkyl, (C1-C3) haloalkyl, (C1-C4)hydroxyalkyl, C3-C7 cycloalkyl, hydroxyl and halo; and wherein the asterisk represents the point of attachment for group R11 to the rest of the molecule via X4; 
gdje je R11 sljedeća skupina: [image] u kojoj može biti prisutan R25 i predstavlja jedan, dva ili tri supstituenta koji su neovinso odabrani od sljedećih: C1–C6alkil, (C1–C3) halogenalkil, (C1–C4)hidroksialkil, C3–C7cikloalkil, hidroksil i halogen; te gdje zvjezdica prestavlja mjesto vezanja skupine R11 za ostatak molekule preko X4;
Wherein R11 is a group: Wherein R25 is optionally present and represents one, two or three substituents independently selected in the list consisting of: C1-C6 alkyl, (C1-C3) haloalkyl, (C1-C4)hydroxyalkyl, C3-C7 cycloalkyl, hydroxyl and halo; and wherein the asterisk represents the point of attachment for group R11 to the rest of the molecule via X4; 
gdje je R11 sljedeća skupina: [image] u kojoj može biti prisutan R25 i predstavlja jedan, dva ili tri supstituenta koji su neovinso odabrani od sljedeće skupine: C1–C6alkil, (C1–C3) halogenalkil, (C1–C4)hidroksialkil, C3–C7cikloalkil, hidroksil i halogen; te gdje zvjezdica prestavlja mjesto vezanja skupine R11 na ostatak molekule preko X4;
and pharmaceutically acceptable salts thereof. 
i odgovarajuće farmaceutski prihvatljive soli.
The process according to claim 1, wherein the cleaving agent is trifluoroacetic acid and/or piperidine. 
Postupak u skladu s patentnim zahtjevom 1, pri čemu je agens za cijepanje trifluoroctena kiselina i/ili piperidin.